Notice of Intention to Delist From The London Stock Exchange OKYO Pharma NASDAQOKYO

LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited OKYOOKYO)) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces that it has applied to the UK Financial Conduct Authority (“FCA”) and London Stock Exchange plc (“LSE”) to effect a cancellation of its ordinary shares of no par value each (“Ordinary Shares”) from listing on the standard segment of the FCA’s Official List and trading on the main market for listed securities of the LSE (“Main Market”)…